CMMB News and Press, Chemomab Therapeutics Ltd. From 12/16/21

Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board PR Newswire TEL AVIV, Israel , Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused o...

Chemomab Therapeutics is advancing a first-in-class anti-CCL24 mAb targeting PSC, SSc, and NASH. Lead candidate CM-101 has orphan drug designation by both the FDA and the EMA in its primary indications of PSC and SSc. The company has a cash runway through mid-2023 and has multiple...

Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer - Dr. Weiner Brings Chemomab Extensive Biotechnology and Pharmaceutical Industry R&D and Strategic Experience, Including Overseeing the Design and Management of Clinical Trials for Rare and Chal...

CF Acquisition (NASDAQ:CFVIU) +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition (NASDAQ:DWAC) +23% on deal to take conservative video platform Rumble public Omeros (NASDAQ:OMER) +18% to sell OMID...

Chemomab Therapeutics (NASDAQ:CMMB) soars 15.5% premarket after announcing that the FDA has cleared its Investigational New Drug (IND) application for CM-101, a CCL24-neutralizing antibody for the treatment of the rare disease primary sclerosing cholangitis (PSC). The Phase 2 SPRING...

Chemomab Therapeutics - ADR (NASDAQ:CMMB): Q3 GAAP EPS of -$0.01 beats by $0.01. Cash, cash equivalents of $64.3M Press Release For further details see: Chemomab Therapeutics - ADR EPS beats by $0.01

Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update Expands Senior Management Team While Advancing Two Independent Phase 2 Trials and Preparing to Initiate a Third in Early 2022 PR Newswire TEL AVIV, Israel , Nov...

Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021 --New Preclinical Data Further Supports Ability of CM-101 to Break the Vicious Cycle of Inflammation and Fibrosis in Primary Sclerosing Cholangitis-- PR Newswire TEL AVIV, Israel , N...

Chemomab to Present at Stifel 2021 Virtual Healthcare Conference PR Newswire TEL AVIV, Israel , Nov. 9, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innova...

Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer Seasoned veteran brings Chemomab three decades of diverse life sciences industry experience PR Newswire TEL AVIV, Israel , Nov. 8, 2021 ...